Clinical Observation of Aidi Injection Combined with TP Regimen in the Treatment of Non-small Cell Lung Cancer
10.6039/j.issn.1001-0408.2016.23.23
- VernacularTitle:艾迪注射液联合TP方案治疗非小细胞肺癌的临床观察
- Author:
Zixia SHI
;
Jin ZHANG
;
Bingbing ZHANG
;
Zheng MA
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
TP chemotherapy regimen;
Aidi injection;
Efficacy;
Inflammatory cytokines;
Toxici-ty reaction
- From:
China Pharmacy
2016;27(23):3234-3236,3237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of Aidi injection combined with TP regimen in the treat-ment of non-small cell lung cancer. METHODS:62 patients with non-small cell lung cancer were randomly divided into control group and observation group,31 cases in each group. Control group received TP regimen alone,observation group additionally re-ceived 40 ml Aidi injection,dissolved in 500 ml 0.9% Sodium chloride injection by intravenous infusion. 21 d was a treatment course,and it lasted 4 courses. The level of inflammatory cytokines before and after treatment and post-treatment quality of life, short-term efficacy,patients’satisfaction and toxicity reactions in 2 groups were compared. RESULTS:After treatment,the level of inflammatory cytokines in 2 groups were significantly lower than before,and observation group was lower than control group, the differences were statistically significant (P<0.05). The effective rate of life quality (80.64%) and short-term efficacy (83.87%)in observation group significant were higher than control group(32.25%,64.52%,respectively),the differences were statistically significant (P<0.05). Satisfaction degree (96.77%) in observation group was significantly higher than control group (77.42%);and the incidences of thrombocytopenia,leukopenia,abnormal liver function were significantly lower than control group,the differences were statistically significant (P<0.05). CONCLUSIONS:Aidi injection combined with TP regimen shows good efficacy and little toxicity in the treatment of non-small cell lung cancer,and it helps to reduce the level of inflammatory cyto-kines in patients,improving immune function and the quality of life of patients.
